Literature DB >> 10361135

Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.

S Beà1, M Ribas, J M Hernández, F Bosch, M Pinyol, L Hernández, J L García, T Flores, M González, A López-Guillermo, M A Piris, A Cardesa, E Montserrat, R Miró, E Campo.   

Abstract

Mantle cell lymphomas (MCLs) are characterized by 11q13 chromosomal translocations and cyclin D1 overexpression. The secondary genetic and molecular events involved in the progression of these tumors are not well known. In this study, we have analyzed 45 MCLs (32 typical and 13 blastoid variants) by comparative genomic hybridization (CGH). To identify the possible genes included in the abnormal chromosome regions, selected cases were analyzed for P53, P16(INK4a), RB, C-MYC, N-MYC, BCL2, BCL6, CDK4, and BMI-1 gene alterations. The most frequent imbalances detected by CGH were gains of chromosomes 3q (49%), 7p (27%), 8q (22%), 12q (20%), 18q (18%), and 9q34 (16%) and losses of chromosomes 13 (44%), 6q (27%), 1p (24%), 11q14-q23 (22%), 10p14-p15 (18%), 17p (16%), and 9p (16%). High-level DNA amplifications were identified in 11 different regions of the genome, predominantly in 3q27-q29 (13%), 18q23 (9%), and Xq28 (7%). The CGH analysis allowed the identification of regional consensus areas in most of the frequently involved chromosomes. Chromosome gains (P =. 02) and losses (P =.01) and DNA amplifications (P =.015) were significantly higher in blastoid variants. The significant differences between blastoid and typical tumors were gains of 3q, 7p, and 12q, and losses of 17p. CGH losses of 17p correlated with P53 gene deletions and mutations. Similarly, gains of 12q and high-level DNA amplifications of 10p12-p13 were associated with CDK4 and BMI-1 gene amplifications, respectively. One of 2 cases with 8q24 amplification showed C-MYC amplification by Southern blot. Alterations in 2p, 3q, 13, and 18q were not associated with N-MYC, BCL6, RB, or BCL2 alterations, respectively, suggesting that other genes may be the targets of these genetic abnormalities in MCLs. Increased number of gains (0 v 1-4 v >4 gains per case) (P =.002), gains of 3q (P =.02), gains of 12q (P =.03), and losses of 9p (P =. 003) were significantly associated with a shorter survival of the patients. These results indicate that an increased number of chromosome imbalances are associated with blastoid variants of MCLs and may have prognostic significance.

Entities:  

Mesh:

Year:  1999        PMID: 10361135

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.

Authors:  Javeed Iqbal; Yulei Shen; Yanyan Liu; Kai Fu; Elaine S Jaffe; Cuiling Liu; Zhongfeng Liu; Cynthia M Lachel; Karen Deffenbacher; Timothy C Greiner; Julie M Vose; Sharathkumar Bhagavathi; Louis M Staudt; Lisa Rimsza; Andreas Rosenwald; German Ott; Jan Delabie; Elias Campo; Rita M Braziel; James R Cook; Raymond R Tubbs; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger; Timothy W McKeithan; Wing C Chan
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  Mantle cell lymphoma is characterized by inactivation of the ATM gene.

Authors:  C Schaffner; I Idler; S Stilgenbauer; H Döhner; P Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Authors:  Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

5.  Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

Authors:  Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael Leblanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

6.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 7.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

8.  CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma.

Authors:  Itziar Salaverria; Cristina Royo; Alejandra Carvajal-Cuenca; Guillem Clot; Alba Navarro; Alejandra Valera; Joo Y Song; Renata Woroniecka; Grzegorz Rymkiewicz; Wolfram Klapper; Elena M Hartmann; Pierre Sujobert; Iwona Wlodarska; Judith A Ferry; Philippe Gaulard; German Ott; Andreas Rosenwald; Armando Lopez-Guillermo; Leticia Quintanilla-Martinez; Nancy L Harris; Elaine S Jaffe; Reiner Siebert; Elias Campo; Sílvia Beà
Journal:  Blood       Date:  2012-12-18       Impact factor: 22.113

Review 9.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

Review 10.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.